FDAsafety guidance72% confidence
FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development
Source: FDA
Why This Matters
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Shanghai Haiyan Pharmaceutical Technology Co., Ltd..
Regulatory Analysis
Learn more about actions to accelerate and modernize clinical research across the full continuum of drug development —from the Investigational New Drug (IND) phase to late-stage pivotal trials.
Supporting Context
- Therapeutic area
- Analgesia · Postoperative Pain
- Sub-indication
- Pain
Related signal: YZJ-4729 Shows Promise in Phase Ⅱ Trial for Postoperative Pain Relief